Long-term follow-up of Huntington's disease patients treated with intrastriatal allografts is essential to assess the benefit/risk ratio of grafts as well as their effectiveness. Indeed, some patients are likely to develop adverse effects and the impact of alloimmunisation phenomena remains to be explored.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Progression of the Unified Huntington's Disease Rating Scale (UHDRS) motor score
Timeframe: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed
Progression of the Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP) motor score
Timeframe: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed
Anne-Catherine BACHOUD-LEVI, MD, PhD